Serum Institute of India News
Cyrus Poonawalla founded the Serum Institute of India (SII) in 1966, which is today the world's largest vaccine manufacturer.
Amid an alarming surge of Covid-19 cases in China, the CEO and founder of Serum Institute of India Adar Ponawalla in a tweet has urged the people not to panic. Serum Institute of India is the one who made Covishield covid vaccine.
We must continue to trust and follow the guidelines set by the Government of India, Serum Institute of India (SII) CEO Adar Poonawalla said as he expressed concern over reports of a rising COVID-19 graph in China.
"Since December 2021, we have stopped the production of the Covishield vaccine. We had a stock of a few hundred million doses at that time and of that 100 million doses had already expired," Poonawalla said.
One of the directors of the SII received WhatsApp messages from a person who posed as Adar Poonawalla. The sender asked him to transfer money to certain bank accounts immediately. Believing that it was the CEO who had messaged, the company officials transferred Rs 1.01 crore.
A man has filed a petition seeking a response from the makers of Covishield claiming that the vaccine caused his daughter's death
He has demanded a compensation of Rs 1,000 crore from the Indian-vaccine maker Serum Institute of India (SII)
"The Subject Expert Committee of Drugs Controller General Of India (DCGI) has recommended Serum Institute of India`s (SII) vaccine Covovax for children in the age group of 7-11 years," sources said.
Serum Institute of India is considering setting up its first manufacturing plant in Africa
World`s biggest vaccine maker looks to expand globally after its success in selling Covid-19 shots.
'It`s never been a better time to be a vaccine manufacturer,' SII CEO Adar Poonawalla said at the World Economic Forum.
Adar Poonawalla clarified that the Covid-19 vaccine Covovax is available for everyone above the age of 12 years.
Earlier, on Tuesday, SII CEO had informed that Covovax (Novavax) is now available for children in India.
Covovax was approved by India's drug regulator for restricted use in emergency situations in adults on December 28.
India began inoculating children aged 12-14 from March 16.
Biological E's Corbevax is being used to inoculate them.
The DCGI office had granted SII permission to manufacture and stock Covovax on May 17
The World Health Organisation had on December 17 issued emergency use listing for Covovax
Adar Poonawalla announced the news on Twitter
The vaccine is named CovovaxTM
The Serum Institute of India is the first Indian company to seek approval for the COVID-19 booster dose.
The new Omicron variant was first reported to the WHO by South Africa on November 24.
SII cited adequate stock of the vaccine in the country and a demand for a booster.
The first consignment of Covishield has already left Pune
COVAX is an international COVID-19 vaccine sharing platform
India will start contributing to COVAX after 8 months
SII has urged the Centre to fast-track movement of Covishield domestically and globally.
SII can export 50 Lakh doses of Covishield under COVAX.
Moderna will become the fourth vaccine to be available for use in India
The Centre plans to provide the Moderna doses directly to states
Pfizer will supply one billion doses to India within this year
About 5 million people in Britain are thought to have had the vaccine made by Serum Institute in India
India saw a single-day rise of 46,617 new coronavirus infections
The death toll due to COVID-19 rose to 4,00,312 with 853 daily fatalities
Govt panel has said no to Covovax trial by SII
The panel has asked it to Complete trials on adults first
SII gets DCGI nod to manufacture Sputnik V
It has collaborated with Moscow's Gamaleya Research Institute of Epidemiology and Microbiology
It will manufacture vaccines at its Hadapsar facility
Loading...